XML 64 R28.htm IDEA: XBRL DOCUMENT
v3.20.2

Acquisition and Variable Interest Entity - Additional Information (Detail) $ in Thousands, ¥ in Millions |  | 1 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Sep. 15, 2020 USD ($) | Sep. 15, 2020 CNY (¥) | Oct. 31, 2020 CNY (¥) | Jul. 31, 2020 USD ($) | Jul. 31, 2020 CNY (¥) | Sep. 30, 2020 USD ($) | Sep. 30, 2020 CNY (¥) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 CNY (¥)
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |  |  |  |
Cash consideration | $ |  |  |  |  |  | $ 2,145 |  | $ 0 |
Cash consideration for exchange of outstanding shares |  |  |  |  |  |  | ¥ 7.3 |  |
Subsequent Event [Member] |  |  |  |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |  |  |  |
Cash consideration received |  |  | ¥ 7.3 |  |  |  |  |  |
AstraZeneca AB [Member] |  |  |  |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |  |  |  |
Acquisition costs |  |  |  |  |  |  | ¥ 2.5 |  |
AstraZeneca AB [Member] | Prepaid Expenses and Other Current Assets [Member] |  |  |  |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |  |  |  |
Receivable |  |  |  |  |  | $ 1,400 |  |  | ¥ 9.8
Beijing Falikang Pharmaceutical Co. Ltd [Member] |  |  |  |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |  |  |  |
Percentage of outstanding shares owned |  |  |  |  |  | 51.10% | 51.10% |  |
Investment |  |  |  |  |  | $ 1,500 |  |  | ¥ 10.2
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] |  |  |  |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |  |  |  |
Percentage of outstanding shares acquired |  |  |  |  | 100.00% |  |  |  |
Cash consideration |  |  |  | $ 2,100 | ¥ 15.0 |  |  |  |
Transaction costs |  |  |  |  | 5.0 |  |  |  |
Acquisition costs |  |  |  | 400 | ¥ 2.5 |  |  |  |
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | Beijing Falikang Pharmaceutical Co. Ltd [Member] | AstraZeneca AB [Member] |  |  |  |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |  |  |  |
Percentage of outstanding shares sold in exchange for cash consideration | 48.90% | 48.90% |  |  |  |  |  |  |
Cash consideration for exchange of outstanding shares | $ 1,000 | ¥ 7.3 |  |  |  |  |  |  |
Percentage of outstanding shares owned | 51.10% | 51.10% |  |  |  |  |  |  |
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | Acquired License [Member] |  |  |  |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |  |  |  |
Entire purchase price | $ |  |  |  | $ 2,500 |  |  |  |  |

X
- Definition Acquisition and variable interest entity line items. + References No definition available. + Details
Name: | fgen_AcquisitionAndVariableInterestEntityLineItems
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of outstanding shares of acquiree sold by acquirer. + References No definition available. + Details
Name: | fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer
Namespace Prefix: | fgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of the entity's equity method investment which has been sold. + References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentSoldCarryingAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_RelatedPartyTransactionDueFromToRelatedParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685 + Details
Name: | us-gaap_VariableInterestEntityOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=fgen_AstraZenecaABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AcquiredLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |